Sign Up For Our FREE E-mail Newsletter-> HERE <-To Receive Our Penny Stock Expert Picks Now!
Visit our Twitter page for real-time updates, click here: Penny Stock Experts
Hi Everyone & Welcome New Subscribers,
TPIV (TapImmune, Inc.) has been the center of attention on our blog over the past couple months, and further proved why today following an exciting announcement before the open which set the precedent for the day.
The company announced their plans to present new data at the upcoming San Antonio Breast Cancer Symposium (SABCS) this upcoming Thursday, December 10th.
Shares battled major resistance early in the session between .75-.76, but once they broke through that level for good there was no looking back as the stock made it’s way all the way to .88, and closed the day up nearly 16% at .861 per share.
TPIV (TapImmune, Inc.) is also expecting Orphan Drug Designation Approval from the FDA over the short term as well as a potential Fast Track designation for their folate alpha receptor breast cancer vaccine.
We are excited for what the company might present Thursday and would suggest watching any potential dips in the stock between now and then.
Sign up-> NOW <-To Join Our E-mail List!
Please read our legal Disclaimer below:
We continue trade up to 100,000 shares of TPIV which we have purchased on the open market with our own money. We have no communication with the company nor any affiliates. We may add to this position or sell it entirely at any time. We have no position at this time.
Neither Todayspickis.com nor any of its employees, affiliates, subsidiaries, or family members are registered investment advisers or registered st ock brokers either within the U.S. Securities and Exchange Commission (the “SEC”) or with any state securities regulatory authority and shall not be liable for any direct, indirect, incidental, special or consequential damages arising out of, or resulting from the use or inability to use this site, including but not limited to damages for the loss of capital, funds, profits, use, data, or any and all other possible damages, even if such party has been advised of the possibility of such damages resulting from the use of this site and all information contained on this site.
We are neither licensed nor qualified to provide investment advice. The information contained on our website or in any of our newsletters should be viewed as commercial advertisement and is not intended to be investment advice. Any information found on our website, or in any of our newsletters is not provided to any particular individual with a view toward their individual circumstances. The information contained on our website, and in any newsletter we distribute, is not an offer to buy or sell securities. We distribute opinions, comments, and information free of charge exclusively to individuals who wish to receive them.
Our newsletter and website have been prepared for informational purposes only and are not intended to be used as a complete source of information on any particular company. An individual should never invest in the securities of any of the company’s profiled based solely on information contained in our newsletter or website.
Individuals should assume that all information contained on our website or in one of our newsletters about profiled companies is not trustworthy unless verified by their own independent research. Todayspickis.com may buy or sell shares on the open market that may positively or negatively affect the stock price before or after this mailing and subscribers are to be fully aware that Todayspickis.com and it’s affiliates can buy or sell more shares at any time. We can add or decrease this position at anytime following this e-mail or post. Todayspickis.com and/or it’s affiliates may receive compensation for e-mail alerts.
To view our full compensation disclosure please visit www.Todayspickis.com/Disclaimer.html. Todayspickis.com does not accept free-trading shares as a form of payment.